{
    "clinical_study": {
        "@rank": "102703", 
        "arm_group": [
            {
                "arm_group_label": "Naftifine Hydrochloride Cream 2%", 
                "arm_group_type": "Experimental", 
                "description": "Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.)"
            }, 
            {
                "arm_group_label": "Naftin\u00ae (Naftifine Hydrochloride) Cream 2%", 
                "arm_group_type": "Active Comparator", 
                "description": "Naftin\u00ae (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC)"
            }, 
            {
                "arm_group_label": "Placebo Topical Cream", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo Topical Cream (Taro Pharmaceuticals Inc.)"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to compare the efficacy and safety of the test formulation of\n      Naftifine Hydrochloride Cream 2% to Naftin\u00ae (Naftifine Hydrochloride) 2% Cream in a 6 week\n      study in patients with tinea pedis."
        }, 
        "brief_title": "Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin\u00ae Cream 2% in Patients With Tinea Pedis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Tinea Pedis", 
        "condition_browse": {
            "mesh_term": [
                "Tinea", 
                "Tinea Pedis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or non-pregnant, non-lactating females 18 years or older\n\n          -  Clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces\n             or predominantly interdigital, but may extend to other areas of the foot\n\n          -  The presence of interdigital tinea pedis infection\n\n          -  The sum of the clinical signs and symptoms scores of the target lesion is at least 4,\n             including a minimum score of at least 2 for erythema and a minimum score of 2 for\n             either scaling or pruritus\n\n        Exclusion Criteria:\n\n          -  Females who are pregnant, lactating or planning to become pregnant during the study\n             period\n\n          -  Use of antipruritics, including antihistamines within 72 hours prior to baseline\n             visit\n\n          -  Use of topical corticosteroids, antibiotics or antifungal therapies within two weeks\n             prior to baseline visit\n\n          -  Use of systemic corticosteroids, antibiotics or antifungal therapies within one month\n             prior to baseline visit\n\n          -  Use of oral terbinafine or itraconazole within two months prior to baseline visit\n\n          -  Use of immunosuppressive medication or radiation therapy within three months prior to\n             baseline visit\n\n          -  Any known hypersensitivity to Naftifine Hydrochloride, or any component of the\n             formulation\n\n          -  Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface\n\n          -  History of significant or current evidence of chronic infectious disease, system\n             disorder, organ disorder, or other medical condition that would place undue risk by\n             participation or could jeopardize the integrity of study evaluations\n\n          -  Evidence of any concurrent dermatophytic infection of the toe nails or dermatological\n             condition of the foot that may interfere with tinea pedis evaluation\n\n          -  Past history of dermatophyte infections with a lack of response ot antifungal therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "890", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132260", 
            "org_study_id": "NFTC 1301"
        }, 
        "intervention": [
            {
                "arm_group_label": "Naftifine Hydrochloride Cream 2%", 
                "description": "Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks", 
                "intervention_name": "Naftifine Hydrochloride Cream 2%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Naftin\u00ae (Naftifine Hydrochloride) Cream 2%", 
                "description": "Naftin\u00ae (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.", 
                "intervention_name": "Naftin\u00ae (Naftifine Hydrochloride) Cream 2%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Topical Cream", 
                "description": "Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.", 
                "intervention_name": "Placebo Topical Cream", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Naftifine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Naftifine", 
            "Naftin\u00ae", 
            "Tinea pedis"
        ], 
        "lastchanged_date": "May 5, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) and the Naftin\u00ae (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) in Patients With Tinea Pedis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The proportion of subjects with therapeutic cure (both mycological cure and clinical cure) at the test-of-cure visit conducted four weeks after the end of treatment.", 
            "measure": "Therapeutic Cure", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132260"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Taro Pharmaceuticals USA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Taro Pharmaceuticals USA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}